Company: PRME
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001628280-25-018704
Chunk: 24

Company: Prime Medicine, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 24
---
 exchange rules, our compensation committee determined that no relationships existed that would create a conflict of interest or that would compromise Alpine Rewards’ independence, and that Alpine Rewards is independent pursuant to the independence standards set forth in the Nasdaq listing standards promulgated pursuant to Section 10C of the Exchange Act.

#### Nominating and Corporate Governance Committee
Among other things, our nominating and corporate governance committee’s responsibilities include:

• developing and recommending to the Board criteria for Board and committee membership;

• establishing procedures for identifying and evaluating Board candidates, including nominees recommended by stockholders;

• to the extent deemed appropriate, retaining third-party search firms or other advisors to identify and evaluate director nominee candidates;

<div align='center'>14</div>

• reviewing the composition of the Board to ensure that it is composed of members containing the appropriate skills and expertise to advise us;

• identifying individuals qualified to become members of the Board;

• recommending to the Board the persons to be nominated for election as directors and to each of the Board’s committees;

• developing, recommending to the Board and periodically assessing the adequacy of a set of corporate governance guidelines and a code of conduct and business ethics;

• overseeing the evaluation of our Board; and

• reviewing and discussing with the Board corporate succession plans for our Chief Executive Officer and our other key officers.

The members of our nominating and corporate governance committee are David Schenkein, Wendy Chung and Thomas Cahill. Dr. Schenkein chairs our nominating and corporate governance committee. Our Board has determined that each member of our nominating and corporate governance committee satisfies the independence standards of the applicable rules of Nasdaq. Our nominating and corporate governance committee charter, which has been adopted by our Board, is available on our website.

During the fiscal year ended December 31, 2024, our nominating and corporate governance committee met one time.

#### Board Meetings and Attendance
Our full Board held six meetings during the year ended December 31, 2024. Each of our incumbent directors, except for Robert Nelsen, attended in person or participated via teleconference at least 75% of the aggregate meetings of our Board and the committees of our Board on which he or she served during the year ended December 31, 2024 (in each case, which were held during the period for which he or she was a director and/or a member of the applicable committee and excluding any meetings in which a director was an interested party). Our non-employee directors met in executive session during each of the regularly